Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
NCT01848561 · View on ClinicalTrials.gov ↗
Study Summary
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.
Conditions Studied
Study Locations (20)
California
- Southern California Res. Ctr. /ID# 116898 — Coronado
- Moores Cancer Center at UC San Diego /ID# 133722 — La Jolla
- McGuire, Jr. La Mirada, CA /ID# 116257 — La Mirada
- Atay, Los Alamitos, CA /ID# 110175 — Los Alamitos
- Temecula Valley Endoscopy Ctr /ID# 118660 — Murrieta
- Community Clinical Trials, CA /ID# 117335 — Orange
- Digestive Care Medical Center /ID# 122075 — San Carlos
- Precision Research Institute - San Diego /ID# 103638 — San Diego
- Precision Research Institute - San Diego /ID# 113445 — San Diego
- Santa Monica Research Institut /ID# 118675 — Santa Monica
- Duplicate_St. Joseph Heritage Group - Yorba Linda /ID# 133721 — Yorba Linda
Alabama
- Birmingham Gastroenterology Associates P.C /ID# 102063 — Birmingham
- University of Alabama at Birmingham - Main /ID# 131646 — Birmingham
- Longwood Research /ID# 118662 — Huntsville
- East View Medical Research, LLC /ID# 116259 — Mobile
- Mobile Medical & Diagnostic Center, AL /ID# 102064 — Mobile
Arizona
- HOPE Research Institute /ID# 127947 — Phoenix
- Duplicate_University of Arizona Cancer Center - North Campus /ID# 140387 — Tucson
- University Of Arizona /ID# 117836 — Tucson
Arkansas
- Arkansas Gastroenterology /ID# 113898 — North Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,250 participants |
| Start Date | 2013-04-29 |
| Est. Completion | 2028-06 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01848561
The ClinicalTrials.gov registry entry for NCT01848561 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 8,250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 603 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Ulcerative Colitis (UC) appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01848561 reports 20 study locations spanning 4 distinct geographic areas — top geographies include California, Alabama, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01848561 about?
NCT01848561 is a clinical study titled "A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)". This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.
What is the current status of trial NCT01848561?
This trial is currently active not recruiting. The enrollment target is 8,250 participants. The study started on 2013-04-29. Estimated completion is 2028-06.
What conditions does trial NCT01848561 study?
This clinical trial studies the following conditions: Ulcerative Colitis (UC). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT01848561?
This trial is sponsored by AbbVie, which has 603 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01848561 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.